Page 42 - Breakthrough Device News Today

Home / Top News / Renalytix Commends HHS/CMS on Finalization of MCIT Rule to Provide National Medicare Coverage for FDA Breakthrough Devices and Diagnostics Renalytix Commends HHS/CMS on Finalization of MCIT Rule to Provide National Medicare Coverage for FDA Breakthrough Devices and Diagnostics Creates Pathway for Beneficiary Access to KidneyIntelX for Medicare Beneficiary Kidney Disease Populations NEW YORK, Jan. 13, 2021 (GLOBE NEWSWIRE) — The Centers for Medicaid & Medicare (CMS) announced...

About RenalytixAI RenalytixAI (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Companys lead product is KidneyIntelX.com (visit www.kidneyintelx.com ) which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for d...

Financial Institutions, Inc. Schedules Fourth Quarter and Full Year 2020 Earnings Release and Conference Call Financial Institutions, Inc. Schedules Fourth Quarter and Full Year 2020 Earnings Release and Conference Call WARSAW, N.Y., Jan. 06, 2021 — Financial Institutions, Inc. (NASDAQ:FISI) (the “Company”), the parent company of Five Star Bank, SDN Insurance Agency, LLC (“SDN”), Courier Capital, LLC (“Courier Capital”) and HNP Capital, LLC (“HNP Capital”), will release result...

Kofax Announces ReadSoft Online Integration with Microsoft Dynamics 365 for Invoice & Accounts Payable Automation Kofax Announces ReadSoft Online Integration with Microsoft Dynamics 365 for Invoice & Accounts Payable Automation Kofax, a leading supplier of intelligent automation software for digital workflow transformation, today announces the integration of ReadSoft Online, its software-as-a-service (SaaS) solution for invoice data extraction and accounts payable automation, with the Microsoft...

Share this article Share this article CARLSBAD, Calif., Jan. 6, 2021 /PRNewswire/ -- SOLVD Health (www.solvdhealth.com), a privately held company focused on preventing disease by making actionable and contextual health information accessible to everyone, is preparing to launch a U.S. clinical study of its non-invasive colorectal cancer (CRC) screening test, LifeKit® Prevent. The test is being developed in partnership with Metabiomics, a subsidiary of SOLVD Health. The PREVENT study protocol is...

TricValve Transcatheter Bicaval Valves System granted Designation as Breakthrough Device by the U.S. Food and Drug Administration (FDA) Transcatheter Bicval Valves System by the U.S. Food & Drug Administration on December 15 th 2020. The TricValve is a system of two self-expanding biological valves for the treatment of patients with hemodynamically relevant tricuspid insufficiency and caval reflux. " The TricValve system represents a new technology offering a potentially simple, relatively ...

TricValve® Transcatheter Bicaval Valves System granted Designation as Breakthrough Device by the U.S. Food and Drug Administration (FDA) 22/12/2020 - 16:10 ); ); VIENNA, Dec. 22, 2020 /PRNewswire/ -- P+F Products + Features GmbH has been granted designation as a Breakthrough Device for the companys lead product, the TricValve® Transcatheter Bicval Valves System by the U.S. Food & Drug Administration on December 15th 2020. The TricValve® is a system of two self-expanding biological valves for...

Worldwide Ventricular Assist Device Industry to 2025 - North America Dominates the Market December 21, 2020 07:38 ET | Source: Research and Markets Research and Markets Dublin, IRELAND ResearchAndMarkets.coms offering. The ventricular assist device (VAD) market is anticipated to record a CAGR of about 7.23% during the forecast period. The major factors attributing to the growth of the ventricular assist device market are technological advancement o...

Press release content from PR Newswire. The AP news staff was not involved in its creation. Occlutech’s Atrial Flow Regulator (AFR) Receives U.S. FDA Breakthrough Device Designation December 18, 2020 GMT SCHAFFHAUSEN, Switzerland, Dec. 18, 2020 /PRNewswire/ -- Occlutech, a privately-held company, announced today that the US Food and Drug Administration (FDA) has granted the company a Breakthrough Device designation for its first-in-class, implantable Atrial Flow Regulator (AFR) for Pulmonary ...

Occlutechs Atrial Flow Regulator (AFR) Receives U.S. FDA Breakthrough Device Designation SCHAFFHAUSEN, Switzerland, Dec. 18, 2020 /PRNewswire/ -- Occlutech, a privately-held company, announced today that the US Food and Drug Administration (FDA) has granted the company a Breakthrough Device designation for its first-in-class, implantable Atrial Flow Regulator (AFR) for Pulmonary Arterial Hypertension (PAH). PAH affects hundreds of thousands in the U.S. and globally and is resulting from change...